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Abstract: BACKGROUND Hypoxic-ischaemic encephalopathy (HIE) is a serious birth complication af-
fecting term and late preterm newborns. Although therapeutic hypothermia (cooling) has been shown
to be an effective therapy for neonatal HIE, many cooled infants have poor long-term neurodevelopmen-
tal outcomes. In animal models of neonatal encephalopathy, inhaled xenon combined with cooling has
been shown to offer better neuroprotection than cooling alone. OBJECTIVES To determine the effects
of xenon as an adjuvant to therapeutic hypothermia on mortality and neurodevelopmental morbidity,
and to ascertain clinically important side effects of xenon plus therapeutic hypothermia in newborn
infants with HIE. To assess early predictors of adverse outcomes and potential side effects of xenon.
SEARCH METHODS We used the standard strategy of the Cochrane Neonatal Review Group to search
the Cochrane Library (2017, Issue 8), MEDLINE (from 1966), Embase (from 1966), and PubMed (from
1966) for randomised controlled and quasi-randomised trials. We also searched conference proceedings
and the reference lists of cited articles. We conducted our most recent search in August 2017. SELEC-
TION CRITERIA We included all trials allocating term or late preterm encephalopathic newborns to
cooling plus xenon or cooling alone, irrespective of timing (starting age and duration) and concentrations
used for xenon administration. DATA COLLECTION AND ANALYSIS Two review authors indepen-
dently assessed results of searches against predetermined criteria for inclusion, assessed risk of bias, and
extracted data. We performed meta-analyses using risk ratios (RRs), risk differences (RDs), and num-
ber needed to treat for an additional beneficial outcome (NNTB) with 95% confidence intervals (CIs)
for dichotomous outcomes and mean differences (MDs) for continuous data. MAIN RESULTS A single
randomised controlled trial enrolling 92 participants was eligible for this review. Researchers have not
reported long-term neurodevelopmental outcomes, including the primary outcome of this review - death
or long-term major neurodevelopmental disability in infancy (18 months to three years of age). Cooling
plus xenon was not associated with reduced mortality at latest follow-up, based upon low quality evi-
dence. Investigators noted no substantial differences between groups for other secondary outcomes of this
review, such as biomarkers of brain damage assessed with magnetic resonance imaging and occurrence of
seizures during primary hospitalisation. Available data do not show an increased adverse event rate in the
cooling plus xenon group compared with the cooling alone group. AUTHORS’ CONCLUSIONS Current
evidence from one small randomised controlled pilot trial is inadequate to show whether cooling plus
xenon is safe or effective in near-term and term newborns with HIE. Further trials reporting long-term
neurodevelopmental outcomes are needed.
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A B S T R A C T
Background
Hypoxic-ischaemic encephalopathy (HIE) is a serious birth complication affecting term and late preterm newborns. Although thera-
peutic hypothermia (cooling) has been shown to be an effective therapy for neonatal HIE, many cooled infants have poor long-term
neurodevelopmental outcomes. In animal models of neonatal encephalopathy, inhaled xenon combined with cooling has been shown
to offer better neuroprotection than cooling alone.
Objectives
To determine the effects of xenon as an adjuvant to therapeutic hypothermia on mortality and neurodevelopmental morbidity, and to
ascertain clinically important side effects of xenon plus therapeutic hypothermia in newborn infants with HIE. To assess early predictors
of adverse outcomes and potential side effects of xenon.
Search methods
We used the standard strategy of the Cochrane Neonatal Review Group to search the Cochrane Library (2017, Issue 8), MEDLINE
(from 1966), Embase (from 1966), and PubMed (from 1966) for randomised controlled and quasi-randomised trials. We also searched
conference proceedings and the reference lists of cited articles. We conducted our most recent search in August 2017.
Selection criteria
We included all trials allocating term or late preterm encephalopathic newborns to cooling plus xenon or cooling alone, irrespective of
timing (starting age and duration) and concentrations used for xenon administration.
Data collection and analysis
Two review authors independently assessed results of searches against predetermined criteria for inclusion, assessed risk of bias, and
extracted data.We performedmeta-analyses using risk ratios (RRs), risk differences (RDs), and number needed to treat for an additional
beneficial outcome (NNTB)with 95%confidence intervals (CIs) for dichotomous outcomes andmeandifferences (MDs) for continuous
data.
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Main results
A single randomised controlled trial enrolling 92 participants was eligible for this review. Researchers have not reported long-term
neurodevelopmental outcomes, including the primary outcome of this review - death or long-termmajor neurodevelopmental disability
in infancy (18 months to three years of age). Cooling plus xenon was not associated with reduced mortality at latest follow-up, based
upon low quality evidence. Investigators noted no substantial differences between groups for other secondary outcomes of this review,
such as biomarkers of brain damage assessed withmagnetic resonance imaging and occurrence of seizures during primary hospitalisation.
Available data do not show an increased adverse event rate in the cooling plus xenon group compared with the cooling alone group.
Authors’ conclusions
Current evidence from one small randomised controlled pilot trial is inadequate to show whether cooling plus xenon is safe or effective
in near-term and term newborns with HIE. Further trials reporting long-term neurodevelopmental outcomes are needed.
P L A I N L A N G U A G E S U M M A R Y
Cooling plus inhaled xenon for newborns with hypoxic-ischaemic encephalopathy
Review question: How does cooling plus inhaled xenon compare with cooling alone for improving survival and development of
newborn babies who may have suffered from lack of oxygen at birth?
Background: Hypoxic-ischaemic encephalopathy, or HIE, is a brain injury caused by oxygen deprivation to the brain during birth
(birth asphyxia). Hypoxic-ischaemic encephalopathy is a leading cause of death or severe impairment among infants. Therapeutic
hypothermia (cooling) is a treatment option available to reduce the chances of severe brain damage when an infant’s body temperature
is reduced shortly after birth. Although cooling has been shown to be an effective therapy for neonatal HIE, half of treated newborn
babies still die or face neurodevelopmental sequelae later in life. Evidence indicates that inhaled xenon, an odourless gas, in combination
with body cooling, can help to improve survival and development at 18 to 36 months.
Study characteristics: This review found a single randomised controlled trial that examined the short-term effects of cooling plus
xenon for infants with HIE.
Key results: This trial enrolled 92 participants. Cooling plus xenon did not improve clinical outcomes before discharge from the
hospital compared with cooling alone. Data on long-term development were not provided.
Quality of evidence:Current lowquality evidence is inadequate to showwhether cooling plus xenon improves survival and development
of newborn babies with HIE. Evidence is up-to-date as of August 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Cooling plus xenon compared with cooling alone for newborns with hypoxic- ischaemic encephalopathy
Patient or population: late preterm or term newborns with hypoxic-ischaemic encephalopathy
Settings: neonatal intensive care unit
Intervention: cooling plus xenon
Comparison: cooling alone
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with cooling alone Risk with cooling plus
xenon
Death or major neu-
rodevelopmental dis-
ability in infancy
No data No data No data No data Absence of evidence
Mortality at latest re-
ported age
Study population RR 1.22
(0.56 to 2.67)
92
(1 RCT)
⊕⊕©©
Low
Single study
Unblinded trial
196 per 1000 239 per 1000
Major neurodevelop-
mental
disability in infancy
No data No data No data No data Absence of evidence
Major neurodevelop-
mental
disability at school age
No data No data No data No data Absence of evidence
Cerebral palsy in in-
fancy
No data No data No data No data Absence of evidence
Developmental delay
or
intellectual
impairment in infancy
No data No data No data No data Absence of evidence
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Blindness vision in in-
fancy
No data No data No data No data Absence of evidence
Sensorineural deaf-
ness in infancy requir-
ing amplification
No data No data No data No data Absence of evidence
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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B A C K G R O U N D
Description of the condition
Intrapartum asphyxia is the third leading cause of child death
globally (Liu 2015). It is estimated that each year, over 0.7 mil-
lion affected newborns die and 1.15 million develop acute disor-
dered brain function known as ’hypoxic-ischaemic encephalopa-
thy (HIE)’ (Lee 2013). HIE, which is one of the most common
causes of childhood neurodisability worldwide, results in consid-
erable psychosocial and economic impact for families and society
(Lawn 2014). Induced therapeutic hypothermia (body cooling)
has emerged as an effective neuroprotective strategy for term and
late preterm newborns with moderate to severe HIE. However, in
the developed world, half of treated infants still die or face neu-
rodevelopmental sequelae later in life (Jacobs 2013).
Human and animal studies have demonstrated that the basic cas-
cade of brain injury related to hypoxic-ischaemic insults typically
occurs in distinct phases (Hassell 2015); in the acute phase, the
culmination of energy failure, acidosis, glutamate release, lipid
peroxidation, and the toxic effect of nitric oxide leads to cell death
via necrosis and activates apoptotic cascades (Ferriero 2004). Af-
ter partial recovery and a latent phase that lasts up to six hours,
secondary deterioration occurs. This secondary phase is charac-
terised by cytotoxic oedema, excitotoxicity, and secondary en-
ergy failure with nearly complete loss of mitochondrial activity
(Douglas-Escobar 2015). In newborns with moderate to severe
HIE, this secondary phase of injury is typically associated with
clinical deterioration and increased seizure activity. Magnetic res-
onance spectroscopy (MRS), which is the most accurate quanti-
tative magnetic resonance biomarker in the neonatal period for
prediction of neurodevelopmental outcome after HIE (Thayyil
2010), shows that this secondary phase is generally accompanied
by a second lactate elevation (Barkovich 1995). A tertiary phase
involves active pathological processes that occur for months after
a hypoxic-ischaemic insult, including late cell death, remodelling
of the injured brain, and astrogliosis due to persistent inflamma-
tion and epigenetic changes (Fleiss 2012). It is the time period
following resuscitation, before the secondary phase of injury, that
provides a potential window for neuroprotection or diminution
of injury.
Description of the intervention
Xenon is an odourless, dense, noble gas that has been approved as
an inhalational anaesthetic in adults. Xenon has a rapid onset of
action via inhalation and is eliminated unchanged via the lungs
within minutes of cessation of delivery. Upon administration,
xenon rapidly decreases amplitude-integrated electroencephalo-
graphic (aEEG) background activity (Sabir 2016), which is consis-
tent with clinical findings that demonstrate its anticonvulsant and
electroencephalographic (EEG) suppressant effects in infants with
HIE (Azzopardi 2013). Small and large preclinical studies have
evaluated its potential as a neuroprotective agent, when inhaled at
a subanaesthetic concentration of 50% (Dingley 2006;Ma 2005).
In animal models of moderate HIE, xenon significantly reduced
brain injury and had an additive neuroprotective effect when com-
bined with cooling immediately after the insult (Chakkarapani
2010; Dingley 2008; Liu 2015; Thoresen 2009). This benefit was
sustained with complete restoration of long-term functional out-
comes and improved regional histopathology (Hobbs 2008).
The optimal timing, dose, and duration of xenon inhalation have
not yet been established. Xenon has been shown to be neuro-
protective in neonatal rats when administered before (Ma 2006),
during (Ma 2005), and after a hypoxic insult (Dingley 2006).
When administered immediately or within hours after a hypoxic-
ischaemic event, xenon had a significant effect at concentrations
of 40% (Xe40%) and greater (Ma 2005). When combined with
therapeutic hypothermia in a hypoxic-ischaemic pig model, xenon
was effective and safe in concentrations up to 70% and for as long
as 24 hours (Chakkarapani 2010; Dingley 2008; Faulkner 2011).
Although Xe70% has been suggested to be more neuroprotective
than Xe50%, most preclinical studies used concentrations ≤ 50%
that induced sedation and allowed administration of substantial
concentrations of oxygen but did not result in respiratory depres-
sion (Dingley 2008).
In the field of adult critical care medicine, the cardiovascular, anal-
gesic, and safety profile of xenon has been thoroughly evaluated
(Dingley 2001; Rossaint 2003; Sanders 2005). In the paediatric
population, however, its safety has not yet been assessed system-
atically. In a piglet model of HIE that closely resembles perina-
tal asphyxia, xenon together with therapeutic hypothermia im-
proved cardiovascular stability and reduced the requirement for
inotropes (Chakkarapani 2012). Investigators noted no increase in
oxygen requirements, no cuffed tracheal tube complications, and
no stridor or extubation delays either during or after xenon de-
livery (Chakkarapani 2010). Despite their favourable short-term
safety profile, considerable controversy surrounds the lasting ef-
fects of anaesthetic agents on the developing brain in general (Sun
2010). Animal studies have demonstrated that general anaesthetic
agents produce accelerated apoptosis and cause adverse effects on
cognition and behaviour (Andropoulos 2017; Jevtovic-Todorovic
2013). Xenon acts mainly by inhibiting theN-methyl-D-aspartate
(NMDA) receptor, but in contrast to other inhalation anaesthetic
agents, xenon lacks dopamine-releasing properties and is not as-
sociated with an increase in neuroapoptosis (Faulkner 2011; Sabir
2013).
Amajor disadvantage of xenon is that it is difficult to use in clinical
practice owing to its scarcity (0.0087 ppm in air) and high costs,
along with the need for closed-circuit delivery (including cuffed
tubes) and recycling systems.
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How the intervention might work
Xenon is an NMDA receptor antagonist that prevents postsynap-
tic binding of the excitatory neurotransmitter glutamate (Franks
1998). It competitively binds to the glycine site of the receptor by
interacting with the aromatic ring of phenylalanine (Armstrong
2012; Dickinson 2007). Researchers have demonstrated the neu-
roprotective properties of xenon in cell culture (Petzelt 2003), in a
rodent model of hypoxia-ischaemia (Dingley 2008; Hobbs 2008;
Ma 2005; Thoresen 2009; Zhuang 2012), and in a neonatal pig
model of global hypoxia-ischaemia (Chakkarapani 2010; Faulkner
2011). Apart from its blocking effect on NMDA receptors, addi-
tional neuroprotective mechanisms have been identified. Xenon
activates two species of potassium channels including the inwardly
rectifying KAT P channel, as reported in Bantel 2010, and the two
pore domain K+channels studied by Gruss 2004, both of which
have been linked to neuroprotection. Other actions include in-
hibition of the calcium/calmodulin-dependent protein kinase II
(Petzelt 2001), as well as activation of the antiapoptotic effec-
tors Bcl-XL and Bcl-2 (Ma 2007). Furthermore, xenon increases
the production of hypoxia-inducible factor 1 alpha (HIF-1 alpha)
and its downstream effectors erythropoietin, vascular endothelial
growth factor, and glucose transporter 1 protein, which can inter-
rupt the apoptotic pathway (Ma 2009).
Through inhibition of NMDA receptors and reduction of apop-
totic cell death, xenon is believed to exert most of its neuroprotec-
tive properties in the early and late phases of reperfusion injury.
Why it is important to do this review
Cooling has been shown to be an effective therapy for neonatal
HIE. However, the rate of death and disability remains at about
50% in treated infants, necessitating the development of addi-
tional neuroprotective therapies. This is the first systematic review
conducted to assess the evidence for xenon as an adjuvant to ther-
apeutic hypothermia for newborns with HIE.
O B J E C T I V E S
To determine the effects of xenon as an adjuvant to therapeutic hy-
pothermia on mortality and neurodevelopmental morbidity, and
to ascertain clinically important side effects of xenon plus thera-
peutic hypothermia in newborn infants with HIE. To assess early
predictors of adverse outcomes and potential side effects of xenon.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) and quasi-
RCTs that compare cooling plus xenon versus cooling alone.
Types of participants
1. Newborn infants at 35 weeks’ gestation or greater with:
i) evidence of peripartum asphyxia, with each enrolled
infant satisfying at least one of the following criteria.
a) Apgar score ≤ 5 at 10 minutes.
b) Mechanical ventilation or resuscitation at 10
minutes.
c) Cord pH < 7.1, or arterial pH < 7.1, or base
deficit ≥ 12 within 60 minutes of birth.
ii) evidence of encephalopathy according to Sarnat
staging (Finer 1981; Sarnat 1976).
a) Stage 1 (mild): hyperalertness, hyperreflexia,
dilated pupils, tachycardia, absence of seizures.
b) Stage 2 (moderate): lethargy, hyperreflexia,
miosis, bradycardia, seizures, hypotonia with weak suck, and
Moro.
c) Stage 3 (severe): stupor, flaccidity, small to mid-
position pupils that react poorly to light, decreased stretch
reflexes, hypothermia, and absent Moro.
iii) induced therapeutic hypothermia treatment (whole
body or selective head cooling to 32°C to 34°C) initiated within
six hours after birth; and
iv) no major congenital abnormalities recognisable at
birth.
Types of interventions
Inhaled xenon (irrespective of timing and concentrations used)
as an adjuvant to therapeutic hypothermia versus therapeutic hy-
pothermia alone, based on the following prespecified definitions.
1. Therapeutic hypothermia.
i) Standard therapeutic hypothermia (whole body or
selective head cooling to 32°C to 34°C initiated within six hours
after birth and continued for 72 hours before slow rewarming.
2. Xenon administration.
i) Irrespective of timing (starting age and duration) and
concentrations used.
Types of outcome measures
Primary outcomes
The primary outcome measure was death or long-termmajor neu-
rodevelopmental disability in infancy (18 months to three years
of age) defined as the following.
1. Cerebral palsy (CP), graded according to the Gross Motor
Function Classification System of Palisano 1997 for children two
years of age and younger.
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2. Developmental delay (Bayley or Griffith assessment more
than two standard deviations (SD) below the mean).
3. Intellectual impairment (intelligence quotient (IQ) more
than two SD below the mean).
4. Blindness (vision < 6/60 in both eyes).
5. Sensorineural deafness requiring amplification.
Secondary outcomes
Secondary outcomes included the following.
1. Mortality (all-cause mortality at latest reported age).
2. Major neurodevelopmental disability:
i) in infancy (18 months to three years of age); and
ii) at school age (> five years).
3. Major neurodevelopmental disability in infancy (18 months
to three years of age) consists of the following components.
i) CP, graded according to the Gross Motor Function
Classification System of Palisano 1997 for children two years of
age and younger.
ii) Developmental delay or intellectual impairment.
a) Bayley or Griffith assessment more than two SD
below the mean or intellectual impairment (IQ more than two
SD below mean).
b) Neuromotor development (Bayley Scales of
Infant Development - Psychomotor Development Index (BSID
PDI)) assessed in survivors.
c) Mental development (Bayley Scales of Infant
Development - Mental Development Index (BSID MDI))
assessed in survivors.
iii) Blindness (vision < 6/60 in both eyes).
iv) Sensorineural deafness requiring amplification.
4. Cognitive and educational outcomes in survivors over five
years of age.
i) IQ and/or indices of educational achievement
measured by a validated assessment tool including school
examination results.
5. Additional predictors of neurodevelopmental outcome.
i) Severity of encephalopathy at enrolment (Sarnat
staging) (Finer 1981; Sarnat 1976).
ii) Severity of EEG abnormality at enrolment.
a) Severe: isoelectric or burst-suppression pattern.
b) Moderate: low voltage or discontinuous
background.
c) Mild: electrographic seizures, dysmaturity.
iii) Seizures.
a) Seizures during initial hospitalisation.
b) Seizures or need for anticonvulsants at follow-up.
iv) Magnetic resonance imaging (MRI) abnormalities
during primary hospitalisation.
a) Moderate or severe abnormalities in the basal
ganglia or thalamus, severe white matter lesions, or abnormalities
in the posterior limb of the internal capsule (Rutherford 2010).
6. Potential adverse effects of xenon therapy during or
immediately after administration.
i) Heart rate.
a) Sinus bradycardia (heart rate < 80 beats/min).
b) Sinus tachycardia (heart rate > 180/min).
c) Prolonged QT interval.
d) Major arrhythmia (requiring medical
intervention or cessation of xenon therapy, or both).
ii) Blood pressure.
a) Hypotension (mean arterial pressure (MAP) < 40
mmHg).
b) Need for inotrope support.
iii) Respiratory impairment.
a) Pneumonia.
b) Pulmonary air leak.
c) Pulmonary haemorrhage.
d) Persistent pulmonary hypertension (PPHN)
(diagnosed clinically or by echocardiogram).
iv) Cuffed endotracheal tube complications.
a) Extubation stridor.
v) Skin rashes.
Search methods for identification of studies
We conducted systematic searches for randomised controlled trials
(RCTs) or quasi-RCTs and considered only parallel-group trials.
We applied no language, publication year, or publication status
restrictions.
Electronic searches
We used the criteria and standard methods of Cochrane and the
Cochrane Neonatal Review Group. We undertook a comprehen-
sive search of the following electronic sources.
We used MeSH terms and keywords to search the following.
1. MEDLINE (1966 to 01 August 2017).
2. Embase (1966 to 01 August 2017).
3. Cochrane Library (01 August 2017; 2017, Issue 8).
We used keywords (to retrieve e-publications and items not in-
dexed in MEDLINE).
1. PubMed (1966 to 01 August 2017).
Others.
1. Conference proceedings of the Perinatal Society of Australia
and New Zealand (from 2005 to 01 August 2017).
2. Conference proceedings of the Pediatric Academic Societies
(from 2000 to 01 August 2017).
We have presented in Appendix 1 the full search strategies for each
database. We screened the reference lists of any cited articles.
Searching other resources
We searched clinical trial registries for ongoing and recently com-
pleted trials (e.g. ClinicalTrials.gov ( clinicaltrials.gov), World
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Health Organization International Trials Registry and Platform,
International Standard Randomised Controlled Trial Number (
ISRCTN) registry ( www.isrctn.com/)).
Data collection and analysis
We used the standard methods of the Cochrane Neonatal Review
Group as described below.
Selection of studies
Two review authors (CR and JC) independently searched and
identified eligible trials that met the inclusion criteria using Covi-
dence, which is an online screening and data extraction tool used
for Cochrane Reviews (Covidence 2017). First, we screened ti-
tles and abstracts to identify potentially relevant citations; then
we retrieved the full text of all potentially relevant articles. We in-
dependently assessed the eligibility of studies in accordance with
the specified inclusion criteria. We reviewed studies for relevance
based on study design and types of participants, interventions, and
outcome measures. We resolved disagreements by discussion and,
if necessary, by consultation with a third review author (PD).
We have provided details of studies excluded from the review in
the Characteristics of excluded studies table, along with reasons
for exclusion. We contacted trial authors if details of primary trials
were unclear.
Data extraction and management
Two review authors (CR and JC) separately extracted, assessed,
and coded all data for each study using an online screening and
data extraction tool for Cochrane Reviews (Covidence 2017). One
review author (CR) checked exported data using Review Manager
5 (RevMan 5) software (Review Manager 2014). A third review
author addressed disagreements.
Assessment of risk of bias in included studies
Two review authors (CR and JC) independently assessed the risk
of bias (as low, high, or unclear) of all included trials using the
Cochrane ’Risk of bias’ tool (Higgins 2011) for the following
domains.
1. Sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding of participants and personnel (performance bias).
4. Blinding of outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective reporting (reporting bias).
7. Any other bias.
We resolved disagreements by discussion or by consultation with
a third review author. See Appendix 2 for a detailed description of
risk of bias for each domain.
Measures of treatment effect
We performed statistical analyses using standard methods of the
Cochrane Neonatal Review Group. We analysed results of studies
using RevMan 5 (Review Manager 2014), and we presented re-
sults as risk ratios (RRs), risk differences (RDs), number needed
to treat for an additional beneficial outcome (NNTB), or number
needed to treat for an additional harmful outcome (NNTH) for
categorical variables. We used mean differences (MDs) for contin-
uous variables. We reported 95% confidence intervals (95% CIs)
for all estimates.
Unit of analysis issues
We included all RCTs and quasi-RCTs. We took into account the
level at which randomisation occurred, including cross-over trials,
cluster-randomised trials, and multiple observations for the same
outcome.
Dealing with missing data
We planned to request additional data from the authors of each
trial if data on important outcomes were missing or needed clari-
fication. When data were still missing, we planned to examine the
effects of losses by performing sensitivity analysis. We performed
these analyses by intention-to-treat.
Assessment of heterogeneity
We assessed statistical heterogeneity by examining the I² statistic
- a quantity that describes the proportion of variation in point
estimates that is due to variability across studies rather than to
sampling error (Higgins 2011). We applied I² statistic cutoffs and
labels for heterogeneity as follows.
1. Less than 25%: no heterogeneity.
2. 25% to 49%: heterogeneity.
3. 50% to 74%: moderate heterogeneity.
4. ≥ 75%: high heterogeneity.
We considered statistical heterogeneity to be substantial when the
I² statistic value was greater than 50%. In addition, we employed
theChi² test of homogeneity to determine the strength of evidence
that heterogeneity is genuine.We explored clinical variation across
studies by comparing the distribution of important participant
factors among trials and trial factors (randomisation concealment,
blinding of outcome assessment, loss to follow-up, treatment type,
and co-interventions). We considered a threshold P value less than
0.1 as an indicator of important heterogeneity (genuine variation
in effect sizes).
Assessment of reporting biases
Weplanned to use funnel plots to assess small-study effects. Owing
to several possible explanations for funnel plot asymmetry, we
planned to interpret results carefully (Sterne 2011).
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Data synthesis
We planned to perform statistical analyses using standard meth-
ods of the Cochrane Neonatal Review Group. We used RevMan
5 software with the fixed-effect model for meta-analysis (Review
Manager 2014). We used standardised mean differences (SMDs)
to combine trials that measured the same outcome using different
methods.We used weightedmean differences (WMDs) with 95%
CIs for outcomes measured on a continuous scale.
Quality of evidence
We used the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) approach, as outlined in the
GRADE Handbook (Schünemann 2013), to assess the quality of
evidence for the following (clinically relevant) outcomes.
1. Death (as above).
2. Major neurodevelopmental disability (as above).
3. Each component of major neurodevelopmental disability
(as above).
Two review authors (CR and JC) independently assessed the qual-
ity of evidence for each of the outcomes above. We considered evi-
dence fromRCTs as high quality but downgraded the evidence one
level for serious (or two levels for very serious) limitations based
upon the following: design (risk of bias), consistency across studies,
directness of evidence, precision of estimates, and presence of pub-
lication bias. We used the GRADEpro Guideline Development
Tool (GRADEpro GDT) to create Summary of findings for the
main comparison to report the quality of evidence.
The GRADE approach yields an assessment of the quality of a
body of evidence using one of four grades.
1. High: we are very confident that the true effect lies close to
that of the estimate of the effect.
2. Moderate: we are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
3. Low: our confidence in the effect estimate is limited: the
true effect may be substantially different from the estimate of the
effect.
4. Very low: we have very little confidence in the effect
estimate: the true effect is likely to be substantially different from
the estimate.
Subgroup analysis and investigation of heterogeneity
We carried out the following subgroup analyses.
1. Severity of HIE.
i) Based on Sarnat score (Finer 1981; Sarnat 1976).
a) Mild versus moderate/severe.
ii) Based on EEG or aEEG at baseline.
a) Mild (electrographic seizures, dysmaturity) versus
moderate/severe (low voltage or discontinuous background/
isoelectric or burst-suppression pattern).
2. Xenon administration.
i) Concentration: < 30% versus ≥ 30%.
ii) Starting age: < six hours versus ≥ six hours after insult.
iii) Duration: < 12 hours versus ≥ 12 hours.
3. Gestational age.
i) Late preterm (35 0/7 through 36 6/7 gestational
weeks) versus term infants (≥ 37 0/7 gestational weeks).
4. Quality of outcome assessment.
i) High quality (≥ 18 months with formal psychological
testing and review by developmental paediatrician for diagnosis
of cerebral palsy (CP)) versus lower quality.
Sensitivity analysis
We conducted sensitivity analyses to explore the effects of method-
ological quality of trials and to ascertain whether studies at high
risk of bias overestimate the effects of treatment.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables.
Results of the search
Weassessed 89 titles and abstracts in electronic format.We assessed
two studies as relevant and determined that one study met the
criteria for inclusion (Figure 1, Study flow diagram).
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Figure 1. Study flow diagram.
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Included studies
Azzopardi 2016
Azzopardi 2016 is a proof-of-concept RCT conducted at four
neonatal intensive care units (NICUs) in the UK between Jan-
uary 2012 and September 2014. Researchers randomised 92 in-
fants at gestational age 36 weeks or greater born with evidence
of peripartum hypoxia-ischaemia (based upon Apgar score ≤ 5
at 10 minutes after birth, continued need for resuscitation 10
minutes after birth, or acidosis within 1 hour of birth), moderate
to severe encephalopathy, and moderately or severely abnormal
background activity or seizures as shown by amplitude-integrated
EEG. Trialists cooled 46 infants in the intervention group to a
target rectal temperature of 33.5°C and provided them with 30%
xenon through anuncuffed endotracheal tube connected to a recir-
culating device developed for the trial. Investigators commenced
xenon immediately after randomisation and continued this for
24 hours. Forty-six infants in the control group received stan-
dard care and were cooled to a target rectal temperature of 33.5°C
with servo-controlled equipment. Researchers started whole-body
cooling within six hours of birth and continued this for 72 hours.
The primary outcome for the study was a reduction in the lac-
tate-to-N-acetyl aspartate ratio in the thalamus and preserved frac-
tional anisotropy in the posterior limb of the internal capsule,
measured by magnetic resonance spectroscopy and magnetic reso-
nance imaging, respectively, within 15 days of birth. Investigators
performed prespecified subgroup analyses of the primary outcome
by severity of the abnormality on aEEG at randomisation, time
from birth to start of xenon therapy, and the relation between
these measures and neurological findings at discharge. Secondary
outcomes includedmaximum ThompsonHIE score, neurological
examination at discharge from the treatment centre, occurrence
of seizures, intracranial haemorrhage, persistent hypotension, pul-
monary haemorrhage, pulmonary hypertension, prolonged blood
coagulation time, thrombocytopaenia, major venous thrombosis,
cardiac arrhythmia, culture-proven late-onset sepsis, necrotising
enterocolitis, pneumonia, pulmonary air leak, anuria or oliguria,
age at which full oral feeding was achieved, duration of hospital
stay, and grade of abnormalities on visual analysis of MRI. Study
authors recorded serious adverse events and included death, hyper-
tension (mean blood pressure > 85 mmHg), hypotension (mean
blood pressure < 25 mmHg), cardiac arrhythmia (severe brady-
cardia (heart rate < 60 beats per minute) or ventricular arrhyth-
mia), and inability to achieve adequate ventilation despite appro-
priate adjustment of ventilator settings. They assessed the primary
outcome in 41 (89%) of 46 infants in the cooling plus xenon
group and in 37 (80%) of 46 infants in the cooling only group.
Lactate-to-N-acetyl aspartate ratio in the thalamus and fractional
anisotropy values in the posterior limb of the internal capsule were
similar in the two groups. The thalamic geometric mean ratio of
lactate to N-acetyl aspartate was 1.09 (95% CI 0.90 to 1.32), and
the mean difference in fractional anisotropy was -0.01 (95% CI -
0.03 to 0.02). Nine (20%) infants in the cooling only group and
11 (24%) infants in the cooling plus xenon group died. Exclusion
of deaths from the analysis did not significantly affect results.
Excluded studies
We excluded from this review one potentially relevant study (
Azzopardi 2013), which was a nested, non-randomised substudy
of a larger RCT (Azzopardi 2016).
Risk of bias in included studies
We judged the included study to be at low risk of bias overall. See
the risk of bias graph (Figure 2) and summary (Figure 3).
11Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Investigators used a computer-generated randomisation sequence.
They concealed allocation to treatment by using a central, web-
based system with telephone backup (low risk of bias).
Blinding
This was an open-label trial. Masking of investigators and parents
to allocation was not feasible because of the need for a special ven-
tilator to administer xenon (high risk of bias). However, investi-
gators who assessed the primary outcome were masked to treat-
ment allocation (low risk of bias). Unblinded assessors assessed
secondary outcomes, but only two of these outcomes were prone
to detection bias (Thompson score and neurological assessment at
discharge; low risk of bias).
Incomplete outcome data
Investigators presented a complete flow chart for all screened and
randomised infants. They randomised a total of 92 infants, 78
(85%) of whom were available for assessment of the primary out-
come - 41 (89%) of 46 in the cooling plus xenon group and 37
(80%) of 46 in the cooling alone group. Five (5%) infants did
not have MRI scans done, although they were alive at discharge
- two (4%) in the cooling plus xenon group and three (7%) in
the cooling alone group. Researchers assessed secondary outcomes
completely.We judged the risk of attrition bias for all outcomes as
low. An additional nine of 92 (9.7%) infants died before discharge
and were excluded from the analysis - three of 46 (6.5%) in the
cooling plus xenon group and six of 46 (13.0%) in the cooling
only group. However, it remains unclear at which postnatal age
these deaths occurred (before or after the prespecified 15-day win-
dow for MRI). Therefore, we decided to rate the risk of attrition
bias for the primary outcome as unclear.
Selective reporting
The study protocol is available, and study authors reported all
prespecified primary and secondary outcomes (low risk of bias).
Other potential sources of bias
We identified no other sources of bias.
Effects of interventions
See: Summary of findings for the main comparison
Comparison 1: cooling plus xenon versus cooling
alone (all infants)
See Summary of findings for the main comparison.
1. Primary outcome.
i) Death or major neurodevelopmental disability: the
included study did not report this outcome.
2. Secondary outcomes.
i) Mortality (Analysis 1.1, Figure 4).
Figure 4. Forest plot of comparison: 1 Cooling plus
xenon versus cooling alone, outcome: 1.1 Mortality.
Figure 8. Forest plot of comparison: 2 Cooling plus xenon versus cooling alone: subgroup analysis by
baseline severity of encephalopathy, outcome: 2.1 Mortality.
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i) Mild encephalopathy (Thompson score 0 to 10): none
of the five infants with mild encephalopathy in the cooling plus
xenon group and none of the two infants with mild
encephalopathy in the cooling alone group died.
ii) Moderate/severe encephalopathy (Thompson score 11
to 22): nine (20%) of 44 infants with moderate/severe
encephalopathy in the cooling plus xenon group and 11 (27%)
of 41 infants with moderate/severe encephalopathy in the
cooling alone group died. Among infants with moderate/severe
encephalopathy, cooling plus xenon was not associated with
reduced mortality at the latest reported age (risk ratio (RR) 1.31,
95% CI 0.61 to 2.84; risk difference (RD) 0.06, 95% CI -0.12
to 0.24; one study and 92 infants; low quality evidence).
1. Major neurodevelopmental disability: the included study
did not report this outcome.
Comparison 3: cooling plus xenon versus cooling alone:
subgroup analysis by baseline amplitude-integrated
electroencephalogram (aEEG) findings
1. Death or major neurodevelopmental disability: the
included study did not report this outcome.
2. Mortality at latest follow-up (Analysis 3.1, Figure 9).
Figure 9. Forest plot of comparison: 3 Cooling plus xenon versus cooling alone: subgroup analysis by
baseline amplitude-integrated electroencephalogram (aEEG) findings, outcome: 3.1 Mortality.
i) Mild aEEG abnormality at baseline: none of the
included infants in the cooling plus xenon group and none of the
infants in the cooling only group had signs of mild aEEG
abnormality at baseline.
ii) Moderate/severe aEEG abnormality at baseline: 11
(24%) of 46 infants with moderate/severe aEEG abnormalities
in the cooling plus xenon group and nine (20%) of 46 infants
with moderate/severe aEEG abnormalities in the cooling alone
group died. Among infants with moderate/severe aEEG
abnormalities at baseline, cooling plus xenon was not associated
with reduced mortality at the latest reported age (risk ratio (RR)
1.22, 95% CI 0.56 to 2.67; risk difference (RD) 0.04, 95% CI -
0.12 to 0.21; one study and 92 infants; low quality evidence).
1. Major neurodevelopmental disability: the included study
did not report this outcome
Comparison 4: cooling plus xenon versus cooling alone:
subgroup analysis by xenon concentration
1. Death or major neurodevelopmental disability: the
included study did not report this outcome.
2. Mortality at the latest follow-up: the included study did not
report this outcome.
3. Major neurodevelopmental disability: the included study
did not report this outcome.
Comparison 5: cooling plus xenon versus cooling alone:
subgroup analysis by gestational age
1. Death or major neurodevelopmental disability: the
included study did not report this outcome.
2. Mortality (Analysis 4.1, Figure 10).
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Figure 10. Forest plot of comparison: 4 Cooling plus xenon versus cooling alone: subgroup analysis by
gestational age, outcome: 4.1 Mortality.
i) Late preterm infants: one (25%) of four late preterm
infants in the cooling plus xenon group and none of two late
preterm infants in the cooling alone group died. Among late
preterm infants with HIE, cooling plus xenon was not associated
with reduced mortality at the latest reported age (risk ratio (RR)
1.80, 95% confidence interval (CI) 0.10 to 31.52; risk difference
(RD) 0.25, 95% CI -0.33 to 0.83; one study and 92 infants).
ii) Term infants: 10 (24%) of 42 term infants in the
cooling plus xenon group and nine (20%) of 44 term infants in
the cooling alone group died. Among term infants with HIE,
cooling plus xenon was not associated with reduced mortality at
the latest reported age (risk ratio (RR) 1.16, 95% CI 0.53 to
2.58; risk difference (RD) 0.03, 95% CI -0.14 to 0.21; one
study and 92 infants; low quality evidence).
1. Major neurodevelopmental disability: the included study
did not report this outcome.
Comparison 6: cooling plus xenon versus cooling alone:
subgroup analysis by quality of follow-up
1. Death or major neurodevelopmental disability: the
included study did not report this outcome.
2. Mortality at the latest follow-up: the included study did not
report this outcome.
3. Major neurodevelopmental disability: the included study
did not report this outcome.
D I S C U S S I O N
Summary of main results
This review identified a single randomised controlled open-label
trial looking at the neuroprotective short-term effects of xenon in
combination with therapeutic hypothermia after birth asphyxia.
The trial randomised 92 newborns withmoderate to severeHIE to
either cooling plus xenon or cooling alone. The primary outcome
- reduction in the lactate-to-N-acetyl aspartate ratio in the thala-
mus and in preserved fractional anisotropy in the posterior limb
of the internal capsule measured with magnetic resonance spec-
troscopy and magnetic resonance imaging, respectively - was not
significantly different between the two groups. Long-term neu-
rodevelopmental outcomes, such as the primary outcome of this
review, were not reported. Researchers found no substantial dif-
ferences between groups for other secondary outcomes, such as
mortality and occurrence of seizures during primary hospitalisa-
tion. Available data do not show an increased adverse event rate
in the cooling plus xenon group compared with the cooling alone
group.
Overall completeness and applicability of
evidence
The neuroprotective effects of xenon as an adjuvant to cooling
have been evaluated only in a single randomised controlled trial.
This trial enrolled a small number of participants and did not re-
port long-term neurodevelopmental outcomes. Moreover, infants
in the intervention group received a relatively low xenon concen-
tration of 30%, and it may well be that use of higher xenon con-
centrations (≥ 40%) is effective in reducing brain injury after hy-
poxic-ischaemic encephalopathy (HIE), as suggested by preclin-
ical studies. Thus, current evidence is inadequate to determine
whether xenon therapy for newborns with HIE is safe or effec-
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tive. Because of its high costs and complex use of xenon in clini-
cal practice, applicability of evidence is restricted to high-resource
settings.
Quality of the evidence
We assessed the quality of evidence for death, major neurodevel-
opmental disability, and each component of major neurodevelop-
mental disability (Summary of findings for themain comparison).
We were able to include only one randomised controlled trial
(RCT) in this review; therefore we were not able to assess the
level of evidence for inconsistency. However, the included trial re-
ported short-term outcomes for the control group (cooling alone)
similar to those seen in the cooled groups of prior cooling trials
(Azzopardi 2014; Gluckman 2005; Shankaran 2005). Owing to
the small sample included and the research question addressed, we
downgraded the level of evidence for imprecision and indirectness.
Although the included trial was at low risk of bias, we judged the
overall quality of evidence as low.
Potential biases in the review process
We are aware of no bias in our review process.
Agreements and disagreements with other
studies or reviews
We are aware of no other systematic reviews on this topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently available evidence does not support the routine use of
xenon as a neuroprotective agent for newborns with HIE and
suggests that this practice should be limited to RCTs.
Implications for research
The biological plausibility of using xenon to prevent HIE injury
has been well established in preclinical studies (Dingley 2006;
Ma 2005), and available clinical data have not raised major safety
concerns related to use of xenon in newborn infants (Azzopardi
2016). Further large trials may be justified and should focus on
effects of various xenon concentrations and timing regimens on
long-term neurodevelopmental outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Azzopardi 2016
Methods Proof-of-concept, randomised, open-label, parallel-group trial done at 4 neonatal inten-
sive care units in the United Kingdom
Participants Included infants born between 36 and 43 weeks’ gestational age with signs of moderate
to severe encephalopathy and moderately or severely abnormal background activity for
at least 30 minutes, or seizures as shown by amplitude-integrated EEG, with 1 of the
following: Apgar score ≤ 5 at 10 minutes after birth, continued need for resuscitation
10 minutes after birth, or acidosis within 1 hour of birth
Excluded infants were older than 6 hours when cooling was started or were older than12
hours at randomisation. Infants were excluded if their oxygen requirement was greater
than 60%, if they needed nitric oxide inhalation or ventilation with a high-frequency
oscillator, if they needed extracorporeal membrane oxygenation, or if they had major
congenital abnormalities
Total number of participants: N = 92
Baseline characteristics:
- Mean (SD) gestational age at delivery (weeks): cooling plus xenon = 39.8 (1.3), cooling
alone = 39.8 (1.3)
-Mean (SD) birthweight (g): cooling plus xenon 3392 (685), cooling alone = 3213 (448)
- Male sex (n): cooling plus xenon = 26 (57%), cooling alone = 21 (46%)
- Median (IQR) Apgar at 10 minutes: cooling plus xenon = 5 (3 to 6), cooling alone =
5 (4 to 7)
- Median (IQR) cord or first blood pH: cooling plus xenon = 6.9 (6.8 to 7.1), cooling
alone = 6.9 (6.7 to 7.0)
- Median (IQR) age cooling commenced (hours): cooling plus xenon = 0.2 (0.0 to 1.5)
, cooling only = 0.3 (0.0 to 0.8)
- Mild HIE at trial entry (n): cooling plus xenon = 5 (11%), cooling alone = 2 (4%)
- Moderate HIE at trial entry (n): cooling plus xenon = 21 (46%), cooling alone = 30
(65%)
- Severe HIE at trial entry (n): cooling plus xenon = 20 (43%), cooling alone = 14 (30%)
- Moderate EEG/aEEG abnormality at trial entry (n): cooling plus xenon = 6 (13%),
cooling alone = 7 (15%)
- Severe EEG/aEEG abnormality at trial entry (n): cooling plus xenon = 40 (87%),
cooling alone = 39 (85%)
Interventions Standard care (n = 46): whole body cooling to a target rectal temperature of 33.5°C for
72 hours starting within 6 hours of birth. If cooling equipment was not available at the
referring hospital, passive cooling was commenced and active cooling was started by the
transport team and continued during transport to the treatment centre
Intervention (n = 46): cooled infants in the inhaled xenon group received 30% xenon
through an uncuffed endotracheal tube connected to a recirculating device developed
for this trial. Xenon was commenced immediately after randomisation and continued
for 24 hours
Intervention characteristics:
- Mean (SD) xenon concentration (%): 32.2 (6.9)
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Azzopardi 2016 (Continued)
- Median (IQR) starting age of xenon administration (hours): 10 (8.2 to 11.2)
- Median (IQR) duration of xenon administration (hours): 24 (24 to 24)
Outcomes Primary: reduction in the lactate-to-N-acetyl aspartate ratio in the thalamus on MRS
or preserved FA in the posterior limb of the internal capsule, measured by magnetic
resonance spectroscopy and MRI, respectively, within 15 days of birth
Secondary: maximum Thompson HIE score, neurological examination at discharge
from treatment centre, occurrence of seizures, intracranial haemorrhage, persistent hy-
potension, pulmonary haemorrhage, pulmonary hypertension, prolonged blood coag-
ulation time, thrombocytopaenia, major venous thrombosis, cardiac arrhythmia, cul-
ture-proven late-onset sepsis, necrotising enterocolitis, pneumonia, pulmonary air leak,
anuria or oliguria, age at which full oral feeding was achieved, duration of hospital stay,
grade of abnormalities on visual analysis of MRI
Identification ClinicalTrials.gov: NCT00934700
ISRCTN: ISRCTN08886155
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate, with a computer-generated ran-
domisation sequence. Assignment done
through a secure web-based system with
telephone backup
Allocation concealment (selection bias) Low risk Adequate, central allocation system
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Study was unblinded with regards to inter-
vention allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Detection bias judged as low risk for pri-
mary outcome and as low risk for secondary
outcomes (see below)
Blinding of outcome assessment (detection
bias)
Secondary outcomes
Low risk Assessors of outcomes unblinded to treat-
ment allocation; however, only 2 secondary
outcomes reliant on assessors (Thompson
score and neurological assessment at dis-
charge). The other outcomes are less likely
to be prone to bias
Blinding of outcome assessment (detection
bias)
Primary outcome
Low risk Investigators who assessed the primary out-
come were masked to treatment allocation
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Azzopardi 2016 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete flow chart of all screened and
randomised infants available. Fourteen (15.
2%) infants were excluded after randomi-
sation, nine (9.7%) of whom died before
discharge
Incomplete outcome data (attrition bias)
Secondary outcomes
Low risk Complete assessment of secondary out-
comes (92/92)
Incomplete outcome data (attrition bias)
Primary outcome
Unclear risk The primary outcome was assessed in 41
(89%) of 46 infants in the cooling plus
xenon group and in 37 (80%) of 46 infants
in the cooling only group. In 2/46 (4.3%)
infants in the cooling plus xenon group
and in 3/46 (6.5%) infants in the cooling
alone group, MRI scans were not done, al-
though infants were alive at discharge. An
additional 9/92 (9.7%) patients died be-
fore discharge and were excluded from the
analysis - 3/46 (6.5%) in the cooling plus
xenon group and 6/46 (13.0%) in the cool-
ing only group. However, it remains un-
clear at which postnatal age these deaths oc-
curred (before or after the prespecified 15-
day window for the MRI). Therefore, we
decided to rate the risk of attrition bias as
“unclear”
Selective reporting (reporting bias) Low risk Study protocol available online; all prespec-
ified primary and secondary outcomes re-
ported
Other bias Low risk None apparent
aEEG: amplitude-integrated electroencephalogram.
EEG: electroencephalogram.
FA: fluorescent antibody.
HIE: hypoxic-ischaemic encephalopathy.
IQR: interquartile ratio.
MRI: magnetic resonance imaging.
MRS: magnetic resonance spectroscopy.
SD: standard deviation.
23Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Azzopardi 2013 Nested, non-randomised substudy of larger randomised controlled trial (Azzopardi 2016)
Characteristics of ongoing studies [ordered by study ID]
NCT01545271
Trial name or title Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth:
Randomised Pilot Study (The CoolXenon2 Study)
Methods Randomised controlled single-centre pilot study in UK
Participants Includes: infants born at ≥ 36 weeks’ gestation WITH clinical evidence of peripartum hypoxia-ischaemia
(Apgar score ≤ 5 at 10 minutes, continued need for resuscitation at 10 minutes, or severe acidosis (pH < 7 or
base deficit≥ 16 mmol/L in cord blood or arterial/venous blood within 60 minutes of birth)) AND abnormal
amplitude-integrated electroencephalogram background AND moderate or severe encephalopathy (Sarnat
criteria) with 1 of hypotonia, abnormal reflexes, absent or weak suck, clinical seizures, or a combination.
For xenon therapy, infants must be intubated with normal partial pressure of CO2 (pCO2), positive end-
expiratory pressure < 6 cm H2O and fraction of inspired oxygen (FiO2) < 0.40, seizures under control,
weighing > 2.3 kg and < 5 hours old, with birthweight greater than the second percentile for age, with no
major congenital anomalies, and haemodynamically stable with no evidence of infection
Excludes: infants considered futile and infants not meeting above criteria
Interventions Standard care: cooling to 33.5°C body temperature, starting within 3 hours after birth
Intervention: cooling to 33.5°C body temperature plus xenon gas at 50% concentration for 18 hours, started
within 5 hours after birth
Outcomes Primary outcomes: amplitude-integrated electroencephalogram (aEEG) grading: number of hours after birth
when aEEG voltage has reached normal or discontinuous normal pattern. Brain MRI findings before 2 weeks
of age
Secondary outcomes: not provided
Starting date May 2012
Contact information Marianne Thoresen, MD
Notes NCT01545271
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NCT02071394
Trial name or title Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth: A
Randomised Pilot Outcomes Study (CoolXenon3 Study)
Methods Randomised controlled pilot outcomes study at 2 centres in the UK
Participants Includes: infants born at ≥ 36 weeks’ gestation WITH clinical evidence of peripartum hypoxia-ischaemia
(Apgar score ≤ 5 at 10 minutes, continued need for resuscitation at 10 minutes, or severe acidosis (pH < 7 or
base deficit≥ 16 mmol/L in cord blood or arterial/venous blood within 60 minutes of birth)) AND abnormal
amplitude-integrated electroencephalogram background AND moderate or severe encephalopathy (Sarnat
criteria) with 1 of hypotonia, abnormal reflexes, absent or weak suck, clinical seizures, or a combination
For xenon therapy, infants must be intubated with normal partial pressure of CO2 (pCO2), positive end-
expiratory pressure < 8 cm H2O and fraction of inspired oxygen (FiO2) < 0.40, seizures under control, < 5
hours old, with birthweight greater than the second percentile for age, with no major congenital anomalies,
and haemodynamically stable
Excludes: infants older than 3 hours of age when cooling started, infants considered futile, and infants not
meeting above criteria
Interventions Standard care: cooling to 33.5°C body temperature, starting within 3 hours after birth
Intervention: cooling to 33.5°C body temperature plus xenon gas at 50% concentration for 18 hours, started
within 5 hours after birth
Outcomes Primary outcomes: death and moderate or severe disability (Bayley III) at 18 months of age
Secondary outcomes: brainMRI within 2 weeks of birth and before hospital discharge, amplitude-integrated
electroencephalogram (aEEG) grading within 1week of birth, number of hours after birth when aEEG voltage
has reached a normal or discontinuous normal pattern, Dubovitz score within 7 days, number of normal
infants (Bayley III composite score ≥ 85 and no neurosensory disability) at 18 to 24 months of age
Starting date March 2014
Contact information Marianne Thoresen, MD
Notes NCT02071394
aEEG: amplitude-integrated electroencephalogram.
CO2: carbon dioxide.
FiO2: fraction of inspired oxygen.
MRI: magnetic resonance imaging.
pCO2: partial pressure of CO2.
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D A T A A N D A N A L Y S E S
Comparison 1. Cooling plus xenon versus cooling alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 92 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.56, 2.67]
2 Adverse event: cardiac
arrhythmia
1 92 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.10, 2.60]
3 Adverse event: persistent
hypotension
1 92 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.79, 1.44]
4 Adverse event: respiratory
impairment
1 92 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.45, 2.89]
Comparison 2. Cooling plus xenon versus cooling alone: subgroup analysis by baseline severity of encephalopathy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 85 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.61, 2.84]
1.1 Infants with moderate/
severe encephalopathy
1 85 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.61, 2.84]
Comparison 3. Cooling plus xenon versus cooling alone: subgroup analysis by baseline amplitude-integrated
electroencephalogram (aEEG) findings
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 92 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.56, 2.67]
1.1 Moderate/severe aEEG 1 92 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.56, 2.67]
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Comparison 4. Cooling plus xenon versus cooling alone: subgroup analysis by gestational age
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 92 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.56, 2.59]
1.1 Late preterm 1 6 Risk Ratio (M-H, Fixed, 95% CI) 1.8 [0.10, 31.52]
1.2 Term 1 86 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.53, 2.58]
Analysis 1.1. Comparison 1 Cooling plus xenon versus cooling alone, Outcome 1 Mortality.
Review: Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy
Comparison: 1 Cooling plus xenon versus cooling alone
Outcome: 1 Mortality
Study or subgroup Cooling plus xenon Cooling alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Azzopardi 2016 11/46 9/46 100.0 % 1.22 [ 0.56, 2.67 ]
Total (95% CI) 46 46 100.0 % 1.22 [ 0.56, 2.67 ]
Total events: 11 (Cooling plus xenon), 9 (Cooling alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Cooling plus xenon Cooling alone
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Analysis 1.2. Comparison 1 Cooling plus xenon versus cooling alone, Outcome 2 Adverse event: cardiac
arrhythmia.
Review: Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy
Comparison: 1 Cooling plus xenon versus cooling alone
Outcome: 2 Adverse event: cardiac arrhythmia
Study or subgroup Cooling plus xenon Cooling alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Azzopardi 2016 2/46 4/46 100.0 % 0.50 [ 0.10, 2.60 ]
Total (95% CI) 46 46 100.0 % 0.50 [ 0.10, 2.60 ]
Total events: 2 (Cooling plus xenon), 4 (Cooling alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Cooling plus xenon Cooling alone
Analysis 1.3. Comparison 1 Cooling plus xenon versus cooling alone, Outcome 3 Adverse event: persistent
hypotension.
Review: Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy
Comparison: 1 Cooling plus xenon versus cooling alone
Outcome: 3 Adverse event: persistent hypotension
Study or subgroup Cooling plus xenon Cooling alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Azzopardi 2016 31/46 29/46 100.0 % 1.07 [ 0.79, 1.44 ]
Total (95% CI) 46 46 100.0 % 1.07 [ 0.79, 1.44 ]
Total events: 31 (Cooling plus xenon), 29 (Cooling alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Cooling plus xenon Cooling alone
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Analysis 1.4. Comparison 1 Cooling plus xenon versus cooling alone, Outcome 4 Adverse event: respiratory
impairment.
Review: Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy
Comparison: 1 Cooling plus xenon versus cooling alone
Outcome: 4 Adverse event: respiratory impairment
Study or subgroup Cooling plus xenon Cooling alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Azzopardi 2016 8/46 7/46 100.0 % 1.14 [ 0.45, 2.89 ]
Total (95% CI) 46 46 100.0 % 1.14 [ 0.45, 2.89 ]
Total events: 8 (Cooling plus xenon), 7 (Cooling alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Cooling plus xenon Cooling alone
Analysis 2.1. Comparison 2 Cooling plus xenon versus cooling alone: subgroup analysis by baseline severity
of encephalopathy, Outcome 1 Mortality.
Review: Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy
Comparison: 2 Cooling plus xenon versus cooling alone: subgroup analysis by baseline severity of encephalopathy
Outcome: 1 Mortality
Study or subgroup Cooling plus xenon Cooling alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Infants with moderate/severe encephalopathy
Azzopardi 2016 11/41 9/44 100.0 % 1.31 [ 0.61, 2.84 ]
Total (95% CI) 41 44 100.0 % 1.31 [ 0.61, 2.84 ]
Total events: 11 (Cooling plus xenon), 9 (Cooling alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Cooling plus xenon Cooling alone
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Analysis 3.1. Comparison 3 Cooling plus xenon versus cooling alone: subgroup analysis by baseline
amplitude-integrated electroencephalogram (aEEG) findings, Outcome 1 Mortality.
Review: Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy
Comparison: 3 Cooling plus xenon versus cooling alone: subgroup analysis by baseline amplitude-integrated electroencephalogram (aEEG) findings
Outcome: 1 Mortality
Study or subgroup Cooling plus xenon Cooling alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Moderate/severe aEEG
Azzopardi 2016 11/46 9/46 100.0 % 1.22 [ 0.56, 2.67 ]
Total (95% CI) 46 46 100.0 % 1.22 [ 0.56, 2.67 ]
Total events: 11 (Cooling plus xenon), 9 (Cooling alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.61)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Cooling plus xenon Cooling alone
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Analysis 4.1. Comparison 4 Cooling plus xenon versus cooling alone: subgroup analysis by gestational age,
Outcome 1 Mortality.
Review: Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy
Comparison: 4 Cooling plus xenon versus cooling alone: subgroup analysis by gestational age
Outcome: 1 Mortality
Study or subgroup Cooling plus xenon Cooling alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Late preterm
Azzopardi 2016 1/4 0/2 6.6 % 1.80 [ 0.10, 31.52 ]
Subtotal (95% CI) 4 2 6.6 % 1.80 [ 0.10, 31.52 ]
Total events: 1 (Cooling plus xenon), 0 (Cooling alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
2 Term
Azzopardi 2016 10/42 9/44 93.4 % 1.16 [ 0.53, 2.58 ]
Subtotal (95% CI) 42 44 93.4 % 1.16 [ 0.53, 2.58 ]
Total events: 10 (Cooling plus xenon), 9 (Cooling alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI) 46 46 100.0 % 1.21 [ 0.56, 2.59 ]
Total events: 11 (Cooling plus xenon), 9 (Cooling alone)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.77), I2 =0.0%
0.01 0.1 1 10 100
Favours cooling/xenon Favours cooling alone
A P P E N D I C E S
Appendix 1. Search strategy
MEDLINE (Ovid)
1. Asphyxia neonatorum/
2. Hyoxia-Ischemia, Brain/
3. exp Anoxia/
4. exp Hypothermia, Induced/ OR hypothermia/
5. Xenon/
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6. (birth or newborn* or neonat* or infan* or gestation* or near-term or term or perinatal or prematur* or pre-term or preterm or
low-birth-weight or LBW or VLBW or (“35” adj5 week*) or (“36” adj5 week*) or (“37” adj5 week*) or (“38” adj5 week*) or (“39”
adj5 week*) or (“40” adj5 week*) or (“41” adj5 week*) or (“42” adj5 week*) or (“43” adj5 week*) or (“44” adj5 week*)).af.
7. (2 or 3) and 4 and 5 and 6
8. 1 and 4 and 5
9. 7 or 8
10. exp animals/ not human*.sh
11. 9 not 10
Embase (Ovid)
1. (birth or newborn* or neonat* or infan* or gestation* or near-term or term or perinatal or prematur* or pre-term or preterm or
low-birth-weight or LBW or VLBW or (“35” adj5 week*) or (“36” adj5 week*) or (“37” adj5 week*) or (“38” adj5 week*) or (“39”
adj5 week*) or (“40” adj5 week*) or (“41” adj5 week*) or (“42” adj5 week*) or (“43” adj5 week*) or (“44” adj5 week*)).af.
2. hypoxic ischaemic encephalopathy/
3. exp asphyxia/
4. brain hypoxia
5. (neonatal adj asphyxial adj seizure*).tw,kw,hw.
6. xenon/
7. hypothermia/
8. induced hypothermia
9. (2 or 3 or 4) and 6 and (7 or 8) and 1
10. 5 and 6 and (7 or 8)
11. 9 or 10
12. exp ANIMAL/ not human*.sh.
13. 11 not 12
Cochrane Library (Wiley)
1. MeSH descriptor: [Asphyxia Neonatorum] this term only
2. Asphyxia* or Hypoxia or Hypoxic or Hypoxemia or Hypoxaemia or Ischemia or Ischaemia or Ischemic or Ischaemic or anoxia or
anoxic (Word variations have been searched)
3. MeSH descriptor: [Hypoxia-Ischemia, Brain] this term only
4. MeSH descriptor: [Anoxia] explode all trees
5. MeSH descriptor: [Hypothermia, Induced] explode all trees
6. MeSH descriptor: [Hypothermia] this term only
7. Hypothermia or Cooling (Word variations have been searched)
8. MeSH descriptor: [Xenon] this term only
9. Xenon or Xe (Word variations have been searched)
10. (35 or 36 or 37 or 38 or 39 or 40 or 41 or 42) next week* (Word variations have been searched)
11. birth or newborn* or neonat* or infan* or gestation* or near-term or “near term” or term or perinatal or prematur* or pre-term
or preterm or “pre term” or “low birth weight” or “low birth-weight” or LBW or VLBW (Word variations have been searched)
12. MeSH descriptor: [Infant] explode all trees
13. (2 or 3 or 4) and (5 or 6 or 7) and (8 or 9) and (10 or 11 or 12)
14. (1) and (5 or 6 or 7) and (8 or 9)
15. 13 or 14
PubMed
1. (birth OR newborn* OR neonat* OR infan* OR gestation* OR near-term OR term OR perinatal OR prematur* OR pre-term
OR preterm OR “pre term” OR “low birth weight” OR “low birth-weight” OR LBW OR VLBW OR ((35 OR 36 OR 37 OR 38
OR 39 OR 40 OR 41 OR 42) AND weeks)) AND (Asphyxia* OR Hypoxia OR Hypoxic OR Hypoxemia OR Hypoxaemia OR
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Ischemia OR Ischaemia OR Ischemic OR Ischaemic) AND (Hypothermia OR Cooling) AND (Xenon OR Xe) AND (NOTNLM
OR publisher[sb] OR inprocess[sb] OR pubmednotmedline[sb] OR indatareview[sb] OR pubstatusaheadofprint)
Appendix 2.
Risk of bias’ tool
We will evaluate the following issues and will enter findings into the Risk of bias’ table.
1. Sequence generation (checking for possible selection bias)
Was the allocation sequence adequately generated?
For each included study, we will categorise the method used to generate the allocation sequence as follows.
1. Low risk (any truly random process, e.g. random number table; computer random number generator).
2. High risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number).
3. Unclear risk.
2. Allocation concealment (checking for possible selection bias)
Was allocation adequately concealed?
For each included study, we will categorise the method used to conceal the allocation sequence as follows.
1. Low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes).
2. High risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth).
3. Unclear risk.
3. Blinding of participants and personnel (checking for possible performance bias)
Was knowledge of the allocated intervention adequately prevented during the study?
For each included study, we will categorise the methods used to blind study participants and personnel from knowledge of which
intervention a participant received. We will assess blinding separately for different outcomes or classes of outcomes. We will categorise
the methods according to the following.
1. Low risk, high risk, or unclear risk for participants.
2. Low risk, high risk, or unclear risk for personnel.
4. Blinding of outcome assessment (checking for possible detection bias)
Was knowledge of the allocated intervention adequately prevented at the time of outcome assessment?
For each included study, we will categorise the methods used to blind outcome assessment. We will assess blinding separately for
different outcomes or classes of outcomes. We will categorise the methods as follows.
1. Low risk for outcome assessors.
2. High risk for outcome assessors.
3. Unclear risk for outcome assessors.
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5. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol
deviations)
Were incomplete outcome data adequately addressed?
For each included study and for each outcome, we will describe the completeness of data including attrition and exclusions from the
analysis. We will note whether attrition and exclusions were reported, numbers included in the analysis at each stage (compared with
the total randomised participants), reasons for attrition or exclusion when reported, and whether missing data were balanced across
groups or were related to outcomes. When sufficient information is reported or supplied by the trial authors, we will re-include missing
data in the analyses. We will categorise methods as one of the following.
1. Low risk (< 20% missing data).
2. High risk (≥ 20% missing data).
3. Unclear risk.
6. Selective reporting bias
Are reports of the study free of the suggestion of selective outcome reporting?
For each included study, we will describe how we investigated the possibility of selective outcome reporting bias and what we found.
We will assess methods as one of the following.
1. Low risk (when it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the review have
been reported).
2. High risk (when not all of the study’s prespecified outcomes have been reported; one or more reported primary outcomes were
not prespecified outcomes of interest and are reported incompletely and so cannot be used; study fails to include results of a key
outcome that would have been expected to have been reported).
3. Unclear risk.
7. Other sources of bias
Was the study apparently free of other problems that could put it at high risk of bias?
For each included study, we will describe any important concerns we had about other possible sources of bias (e.g. whether a potential
source of bias was related to the specific study design, whether the trial was stopped early owing to some data-dependent process). We
will assess whether each study was free of other problems that could put it at risk of bias as follows.
1. Low risk.
2. High risk.
3. Unclear risk.
If needed, we plan to explore the impact of the level of bias through undertaking sensitivity analyses.
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